PL378372A1 - Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii - Google Patents

Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii

Info

Publication number
PL378372A1
PL378372A1 PL378372A PL37837204A PL378372A1 PL 378372 A1 PL378372 A1 PL 378372A1 PL 378372 A PL378372 A PL 378372A PL 37837204 A PL37837204 A PL 37837204A PL 378372 A1 PL378372 A1 PL 378372A1
Authority
PL
Poland
Prior art keywords
efectivenes
terapeutic
radiation
increasing
protein kinase
Prior art date
Application number
PL378372A
Other languages
English (en)
Inventor
Sacha Ninkovic
Michael John Bennett
Yuanjin Rui
Fen Wang
Suzanne Pritchett Benedict
Min Teng
Yong Wang
Jinjiang Zhu
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL378372A1 publication Critical patent/PL378372A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL378372A 2003-01-09 2004-01-05 Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii PL378372A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09

Publications (1)

Publication Number Publication Date
PL378372A1 true PL378372A1 (pl) 2006-04-03

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378372A PL378372A1 (pl) 2003-01-09 2004-01-05 Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii

Country Status (35)

Country Link
US (3) US6967198B2 (pl)
EP (2) EP1585749B1 (pl)
JP (1) JP3990718B2 (pl)
KR (1) KR100697746B1 (pl)
CN (1) CN1759118B (pl)
AP (1) AP2048A (pl)
AT (1) ATE404564T1 (pl)
AU (1) AU2004203977B2 (pl)
BR (1) BRPI0406701A (pl)
CA (1) CA2512683C (pl)
CR (1) CR7899A (pl)
CY (1) CY1108408T1 (pl)
DE (1) DE602004015724D1 (pl)
DK (1) DK1585749T3 (pl)
EA (1) EA009337B1 (pl)
EC (1) ECSP055911A (pl)
ES (1) ES2309484T3 (pl)
GE (1) GEP20084367B (pl)
HK (1) HK1086257A1 (pl)
HR (1) HRP20050624A2 (pl)
IL (1) IL169082A (pl)
IS (1) IS7884A (pl)
MA (1) MA27703A1 (pl)
MX (1) MXPA05007352A (pl)
NO (1) NO20053775L (pl)
NZ (1) NZ540638A (pl)
OA (1) OA13017A (pl)
PL (1) PL378372A1 (pl)
PT (1) PT1585749E (pl)
RS (1) RS20050522A (pl)
SI (1) SI1585749T1 (pl)
TN (1) TNSN05176A1 (pl)
UA (1) UA80733C2 (pl)
WO (1) WO2004063198A1 (pl)
ZA (1) ZA200504674B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1467730A4 (en) * 2002-01-22 2010-03-10 Univ California Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof
ES2309484T3 (es) * 2003-01-09 2008-12-16 Pfizer Inc. Derivados de diazepinoindol como inhibidores de quinasa.
SI1853721T1 (sl) * 2005-02-18 2010-06-30 Astrazeneca Ab Postopek za ugotavljanje odzivnosti na CHK inhibitorje
NZ561458A (en) 2005-03-29 2011-03-31 Icos Corp Heteroaryl urea derivatives useful for inhibiting CHK1
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US8003625B2 (en) 2005-06-29 2011-08-23 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
WO2007022273A2 (en) 2005-08-15 2007-02-22 The Regents Of The University Of California Vegf-activated fas ligands
JP4935675B2 (ja) 2005-08-25 2012-05-23 宇部興産株式会社 光学活性（Ｓ又はＲ）−α−アミノ酸及び光学活性（Ｒ又はＳ）−α−アミノ酸エステルの製造方法
US7645885B2 (en) * 2005-08-26 2010-01-12 The Regents Of The University Of California Non-steroidal antiandrogens
EP2004655A1 (en) * 2006-04-04 2008-12-24 Pfizer Products Incorporated Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4 l)-1-oxo-2,6-dihydro-1h-ý1,2¨diazepinoý4,5,6-cd¨indol-8-yl)acetamide
CA2648371A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
JP2010510222A (ja) * 2006-11-17 2010-04-02 シェーリング コーポレイション 増殖性障害に対する併用療法
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
WO2010016005A1 (en) * 2008-08-06 2010-02-11 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
WO2010040527A1 (en) * 2008-10-10 2010-04-15 Priaxon Ag Novel compounds which modulate kinase activity
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA ACTIVATED DRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
PT2797921T (pt) * 2011-12-31 2017-11-14 Beigene Ltd Dihidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
CN106083849A (zh) 2011-12-31 2016-11-09 百济神州有限公司 作为parp抑制剂的稠合的四元或五元环吡啶并酞嗪酮类化合物
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
ES2733847T3 (es) 2014-06-17 2019-12-03 Vertex Pharma Método para tratar cáncer usando una combinación de inhibidores de CHK1 y ATR
KR20180041748A (ko) * 2015-08-25 2018-04-24 베이진 엘티디 Parp 억제제, 결정형의 제조방법 및 이의 용도
WO2017059357A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
CN110087730B (zh) 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
US10899763B2 (en) 2017-02-28 2021-01-26 Beigene, Ltd. Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
CN111108105B (zh) * 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN113631179A (zh) * 2019-01-25 2021-11-09 努梅迪公司 用于治疗特发性肺纤维化的方法
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
CN114746413B (zh) 2019-11-29 2024-02-23 南京明德新药研发有限公司 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
CA3184988A1 (en) * 2020-07-13 2022-01-20 Ahmed Mamai Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
AU2021318572A1 (en) * 2020-07-31 2023-02-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as PARP inhibitor and method for preparing same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
JP2002526450A (ja) 1998-09-18 2002-08-20 スミスクライン・ビーチャム・コーポレイション Ｃｈｋ１キナーゼ阻害物質
HU229875B1 (en) 1999-01-11 2014-11-28 Agouron Pharmaceuticals Inc La Jolla Tricyclic inhibitors of poly(adp-ribose) polymerases
ATE388226T1 (de) 1999-08-27 2008-03-15 Novartis Vaccines & Diagnostic Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
ES2239037T3 (es) 1999-09-22 2005-09-16 Canbas Co., Ltd. Metodos y composiciones para inhibir la deteccion del ciclo celular en g2 y sensibilizar celulas a agentes dañinos del dna.
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
JP4323802B2 (ja) * 2000-12-01 2009-09-02 エムジーアイ・ジーピー・インコーポレーテッド 化合物およびその使用
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
ES2309484T3 (es) * 2003-01-09 2008-12-16 Pfizer Inc. Derivados de diazepinoindol como inhibidores de quinasa.

Also Published As

Publication number Publication date
KR20050092397A (ko) 2005-09-21
ATE404564T1 (de) 2008-08-15
EA200500893A1 (ru) 2006-02-24
RS20050522A (en) 2007-12-31
WO2004063198A1 (en) 2004-07-29
EP1947102A1 (en) 2008-07-23
BRPI0406701A (pt) 2005-12-20
DE602004015724D1 (de) 2008-09-25
CA2512683C (en) 2010-03-16
CR7899A (es) 2005-08-05
DK1585749T3 (da) 2008-09-22
US20050075499A1 (en) 2005-04-07
AU2004203977B2 (en) 2010-06-17
JP2006516274A (ja) 2006-06-29
HK1086257A1 (en) 2006-09-15
AP2005003353A0 (en) 2005-09-30
AU2004203977A1 (en) 2004-07-29
EP1585749B1 (en) 2008-08-13
GEP20084367B (en) 2008-05-13
OA13017A (en) 2006-11-10
ZA200504674B (en) 2006-07-26
NZ540638A (en) 2007-12-21
MA27703A1 (fr) 2006-01-02
US7462713B2 (en) 2008-12-09
CA2512683A1 (en) 2004-07-29
IL169082A (en) 2011-02-28
MXPA05007352A (es) 2006-02-17
TNSN05176A1 (fr) 2007-06-11
UA80733C2 (en) 2007-10-25
HRP20050624A2 (en) 2006-02-28
ES2309484T3 (es) 2008-12-16
JP3990718B2 (ja) 2007-10-17
SI1585749T1 (sl) 2008-10-31
KR100697746B1 (ko) 2007-03-22
US6967198B2 (en) 2005-11-22
CY1108408T1 (el) 2014-02-12
EA009337B1 (ru) 2007-12-28
CN1759118B (zh) 2010-12-08
US20060004052A1 (en) 2006-01-05
NO20053775D0 (no) 2005-08-08
IS7884A (is) 2005-06-09
AP2048A (en) 2009-09-24
ECSP055911A (es) 2005-11-22
US20070135415A1 (en) 2007-06-14
PT1585749E (pt) 2008-10-23
US7132533B2 (en) 2006-11-07
NO20053775L (no) 2005-09-16
CN1759118A (zh) 2006-04-12
EP1585749A1 (en) 2005-10-19

Similar Documents

Publication Publication Date Title
PL378372A1 (pl) Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii
HK1088332A1 (en) Pyrrolotriazine compounds as kinase inhibitors
HK1199254A1 (en) Process for the preparation of aurora kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
IL167088A (en) Pyrazolopyrimidine derivatives as cyclin dependent kinase inhibitors
PL373338A1 (pl) Związki pirolo-triazynoaniliny użyteczne jako inhibitory kinazy
EP1673343A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
AP2114A (en) Aminoheteroaryl compounds as protein kinase inhibitors
IL183188A0 (en) Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
EP1670771A4 (en) COMPOUNDS AND COMPOSITIONS INHIBITING PROTEIN-KINASES
HK1071757A1 (en) Imidazopyridines as cyclin dependent kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
EP1613595A4 (en) NOVEL COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE
HK1096385A1 (en) Indazole compounds useful as protein kinase inhibitors
EP1503996A4 (en) AS KINASE INHIBITORS SUITABLE ARYLKETONE PYRROLOTRIAZIN COMPOUNDS
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
SI2039685T1 (sl) Heterobiciklične spojine kot P38 inhibitorji
EP1957078A4 (en) PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER BY INHIBITING AURORA KINASE
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
HK1071758A1 (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
EP1713793A4 (en) PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS
AU2003254051A8 (en) Pyrazolopyrimidines as kinase inhibitors

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)